Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for reducing complications of COVID-19
IRCT20170609034406N8Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pentoxifylline in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Serum lactate dehydrogenase level, Serum C-reactive protein level and 7 more. Started Sep 2021; status: completed.
02
Drugs
pentoxifylline
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20170609034406N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170609034406N8.